BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14745870)

  • 1. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
    Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
    Cancer; 2004 Feb; 100(3):538-43. PubMed ID: 14745870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.
    Abramowitz MC; Li T; Buyyounouski MK; Ross E; Uzzo RG; Pollack A; Horwitz EM
    Cancer; 2008 Jan; 112(1):55-60. PubMed ID: 17968996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer.
    Kupelian PA; Ciezki J; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):16-22. PubMed ID: 17996382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
    D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
    Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
    J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy.
    Kramer NM; Horwitz EM; Uzzo RG; Hanlon AL; Hanks GE
    BJU Int; 2004 Jul; 94(1):59-62. PubMed ID: 15217432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Andrews SF; Horwitz EM; Feigenberg SJ; Eisenberg DF; Hanlon AL; Uzzo RG; Pollack A
    Cancer; 2005 Jul; 104(2):299-304. PubMed ID: 15954083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer radiotherapy dose response: an update of the fox chase experience.
    Pollack A; Hanlon AL; Horwitz EM; Feigenberg SJ; Uzzo RG; Hanks GE
    J Urol; 2004 Mar; 171(3):1132-6. PubMed ID: 14767286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
    Thames HD; Kuban D; Levy LB; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Radiother Oncol; 2010 Jul; 96(1):6-12. PubMed ID: 20400191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
    J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.